Why the study?
NLRP3 inflammasome-mediated inflammatory cytokines may participate in metabolic disorders, warranting an overview of NLRP3 regulation and potential targeted drugs.
The NLRP3 inflammasome is a key component of the innate immune system that may serve as a potential therapeutic target for metabolic disorders such as atherosclerosis and diabetes.
NLRP3 inhibition may offer metabolic disease targets; leaves open clinical validation of specific agents.
NLRP3 plays a role in the development of autoinflammatory diseases. NLRP3, ASC, and Caspases 1 or 8 make up the NLRP3 inflammasome, which is an important part of innate immune system. The NLRP3 inflammasome-mediated inflammatory cytokines may also participate in metabolic disorders, such as diabetes, hyperlipidemia, atherosclerosis, non-alcoholic fatty liver disease, and gout. Hence, an overview of the NLRP3 regulation in these metabolic diseases and the potential drugs targeting NLRP3 is the focus of this review.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: